Background: Many cancer patients who receive chemotherapy experience adverse drug
effects. Pharmacogenomics (PGx) has promise to personalize chemotherapy drug dosing to …

Pharmacogenomics (PGx), the study of inherited genomic variation and drug response or
safety, is a vital tool in precision medicine. In oncology, testing to identify PGx variants offers …

Introduction Pharmacogenetics, in hand with precision medicine in oncology, represents an
opportunity to holistically tailor a patient's treatment regimen using both somatic and …

Abstract Background Pharmacogenetic (PGx) testing for germline variants in the DPYD and
UGT1A1 genes can be used to guide fluoropyrimidine and irinotecan dosing, respectively …

BACKGROUND In recent years, there has been increasing evidence supporting the role of
germline pharmacogenomic factors predicting toxicity for anticancer therapies. Although …

Background Fluoropyrimidines (5-fluroouracil (5-FU), capecitabine, FP)) are commonly
prescribed anti-cancer drugs across many tumour streams such as colorectal, gastric and …

Background Fluoropyrimidines (fluorouracil [5-FU], capecitabine) and irinotecan are
commonly prescribed chemotherapy agents for gastrointestinal (GI) malignancies …

Background Despite robust evidence and international guidelines, to support routine
pharmacogenetic (PGx) testing, integration in practice has been limited. This study explored …

Gastrointestinal (GI) malignancies are among the most commonly diagnosed cancers
worldwide. Despite the introduction of targeted and immunotherapy agents in the treatment …

Introduction: Pharmacogenomics is about selecting the “right drug in the right amount for the
right patient.” In metastatic colorectal cancer, germline pharmacogenomics testing presents …